|Agustín Joison* and Federico Gallo|
|Corresponding Author: Agustín Joison, Córdoba Catholic University, Argentina|
|Published: May 01, 2020;|
|Citation: Joison A & Gallo F. (2020) Microplasmin JG: Treatment to Thrombotic Diseases without Risk of Bleeding Events. J Pharm Drug Res, 3(S1): 01.|
|Copyrights: ©2020 Joison A & Gallo F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Plasmin, microplasmin and plasminogen activators are used to treatment different thrombosis, disease characterized to formation of blood clots. This is a cause of death frequently associated with myocardial infarction, stroke, deep-vein thrombosis and pulmonary embolism.
Material & Methods: Microplasmin JG is a low-molecular-weight protein of two molecular chains of 29 and 35 KDa, obtained by plasminogen autolysis in alkaline medium, purified with affinity and anionic interchange chromatography. In vitro (fibrin and fibrin plate) and in vivo (carotid artery thrombosis in rabbits) assays were performed. Fibrinogen, platelets, thrombin time and hematocrit levels were measured before and after microplasmin infusion in rats.
Results: Lysis fibrin clot showed a decrease in the weight (g) respect control (sodium borate buffer) (0.50 ± 0.02 vs. 89.60 ± 3.19) in 25 min. Microplasmin JG showed 25 UI/L activity in fibrin plate. Hematologic parameters showed no decrease either preinfusion and after 48 h injection microplasmin JG treatment: fibrinogen (177 ± 2.18 vs. 170.5 ± 3.75 mg%), platelets 464.083 ± 19.994 vs 509.333 ± 17.812 mm3) , thrombin time (42.41 ± 1.36 vs. 39.80 ± 0.89 seg.) and hematocrit (44 ± 0.56 vs. 46 ± 1.41 %). Doppler in carotid artery thrombosis showed 100% of reperfusion after 15 min.